Alternative Data for Healthcare Investors (Part I): A Primer on Real-World Data

Keava Low, Research Analyst (London)

Neudata Intelligence
Post feature

There is an ever-expanding supply of alternative data sources that can be utilised by pharma, biotech, and medtech investors. In this piece, we turn our attention away from “traditional” clinical trial data towards Real-World Data (RWD). Namely, data that is generated in real-world medical settings. In the first of a series of healthcare-focused Neudata intelligence articles, we provide a primer on the RWD landscape, including 1) an introduction to healthcare data and how RWD is defined, 2) the different types and sources of RWD, and 3) regional differences in the collection and availability of RWD.


For pharma, biotech, and medtech companies, the journey from product discovery to commercialisation is a long and difficult process (it takes at least 10 years, on average, to bring a drug to market),1 and the outcome at each stage of this process can have a significant impact on a company’s financial success. As discussed in our previous piece on using alternative data to evaluate pharmaceutical pipelines, data relating to clinical development success rates (in this case,


Request a Neudata trial

We'd like to know a bit more about you and your business, so we can deal with your request efficiently.
We take your privacy seriously and handle your personal data in line with our privacy statement.

We use your email address as part of allowing you access to your account and in order to provide you details with our products that might be of interest to you